0001317757-12-000006.txt : 20120110
0001317757-12-000006.hdr.sgml : 20120110
20120110161627
ACCESSION NUMBER: 0001317757-12-000006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120109
FILED AS OF DATE: 20120110
DATE AS OF CHANGE: 20120110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: White Christopher G
CENTRAL INDEX KEY: 0001537668
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10865
FILM NUMBER: 12520230
MAIL ADDRESS:
STREET 1: C/O AMAG PHARMACEUTICALS, INC.
STREET 2: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0000792977
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042742593
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 6174983300
MAIL ADDRESS:
STREET 1: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MAGNETICS INC
DATE OF NAME CHANGE: 19920703
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0304
4
2012-01-09
0
0000792977
AMAG PHARMACEUTICALS INC.
AMAG
0001537668
White Christopher G
C/O AMAG PHARMACEUTICALS, INC.
100 HAYDEN AVENUE
LEXINGTON
MA
02421
0
1
0
0
Chief Business Officer and SVP
Common Stock
2012-01-09
4
C
0
8000
A
8000
D
Common Stock
2012-01-09
4
S
0
8000
17.0878
D
0
D
Restricted Stock Units
2012-01-09
4
C
0
8000
D
Common Stock
8000
8000
D
The shares were acquired by the reporting person as a result of the partial vesting of a restricted stock unit grant described below.
Not applicable.
The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
The shares sold on this date were sold in multiple transactions. The price is the weighted average sales price per share of all shares sold on this day. The actual sales prices range from $16.40-$17.81. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
Each restricted stock unit represents a contingent right to receive one share of common stock.
Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests as follows: 50% on January 7, 2012, 25% on January 7, 2013 and the remaining 25% on January 7, 2014.
Joseph L. Farmer, attorney-in-fact
2012-01-10